ASRS-v1.1 — Adult ADHD Self-Report Scale
WHO 6-item screener (Part A) for adult ADHD (Kessler 2005), each item 0–4 (never to very often). This page returns the 0–24 total in Kessler's four strata (≥ 14 positive); the 'darkened box' count (≥ 4 of 6 positive) is on the ASRS v1.1 screen page.
Score interpretation
ASRS total 0–9: ADHD unlikely.
→ Reassure. Address other causes of presenting symptoms (sleep disorder, depression, anxiety, substance use).
ASRS total 10–13: below the positive threshold.
→ Use full ASRS (18 items) to characterise; consider DSM-5 / DIVA-5 structured interview. Refer to specialist adult ADHD service if persistent functional impairment per NICE NG87.
ASRS total 14–17: positive screen.
→ Specialist diagnostic assessment. If diagnosed: psychoeducation, CBT/coaching, occupational adjustments. Pharmacotherapy: methylphenidate / lisdexamfetamine first-line per NICE NG87; atomoxetine alternative. Address comorbidity (depression, anxiety, substance use).
ASRS total 18–24: positive screen, highest stratum.
→ Specialist diagnostic assessment. If diagnosed: psychoeducation, CBT/coaching, occupational adjustments. Pharmacotherapy: methylphenidate / lisdexamfetamine first-line per NICE NG87; atomoxetine alternative. Address comorbidity (depression, anxiety, substance use).
Interpretation bands for the ASRS. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Atomoxetine · Selective Noradrenaline Reuptake Inhibitor (SNRI) — ADHD (Non-Stimulant)
- Sildenafil (Paediatric — PPHN / PAH) · PDE5 Inhibitor (Paediatric Pulmonary Hypertension)
- Methylphenidate · CNS Stimulant — Schedule 2 Controlled Drug (ADHD Treatment)
- Atomoxetine · Selective Noradrenaline Reuptake Inhibitor (SNRI) — Non-stimulant ADHD Treatment
- Lisdexamfetamine · CNS Stimulant (Prodrug) — Schedule 2 Controlled Drug (ADHD / Binge Eating Disorder)
- Guanfacine (Extended-Release) · Alpha-2A Adrenoceptor Agonist (ADHD — Non-Stimulant)
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.